LONDON and NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced that two presentations will…Read More
OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery
